1. Generics and Biosimilars Initiative (GaBi). Biosimilars approved in Europe. December 2018.
http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Europe
. Accessed 02 May 2019.
2. Generics and Biosimilars Initiative (GaBI). EMA accepts application for pegfilgrastim biosimilar from Cinfa. October 2017.
http://www.gabionline.net/Biosimilars/News/EMA-accepts-application-for-pegfilgrastim-biosimilar-from-Cinfa
. Accessed 02 May 2019.
3. US Food and Drug Administration (FDA). FDA Briefing Document—Oncologic Drugs Advisory Committee Meeting. January 2015.
http://patentdocs.typepad.com/files/briefing-document.pdf
. Accessed 02 May 2019.
4. US Food and Drug Administration (FDA). Biosimilar product information. FDA-approved biosimilar products.
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580432.htm
. Accessed 28 June 2019.
5. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, et al. NCCN biosimilars white paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9(Suppl 4):S1–22.